Concurrent with the development of novel therapeutics, early biomarkers for PD and LRRK2 hyperactivation are under extensive investigation, with the aim to enable targeted pharmacological therapies early in disease pathogenesis or at a prodromal stage [122,123]. Here, LRRK2 is linked to Parkinson disease.